1. Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor. (October 2022) Authors: Schram, A.; Borad, M.; Sahai, V.; Kamath, S.; Kim, R.; Liao, C.Y.A.; Oh, D.Y.; Ponz-Sarvisé, M.; Yachnin, J.; Shell, S.A.; Cassier, P.; Dotan, E.; Florou, V.; Moreno, V.; Park, J.O.; Tai, D.; Schmidt-Kittler, O.; Ferté, C.; Goyal, L.; Subbiah, V. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S116 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗